Infectious Mononucleosis and Cancer Risk
If you have been diagnosed with infectious mononucleosis, you are at significantly increased risk for Burkitt lymphoma and Hodgkin lymphoma, not the other cancers listed in your question.
Primary Cancer Associations
The evidence clearly demonstrates that infectious mononucleosis (IM), caused by Epstein-Barr virus (EBV), has a specific cancer risk profile:
Burkitt Lymphoma
- Burkitt lymphoma is directly associated with EBV infection 1
- Post-transplant lymphoproliferative disorders include Burkitt's lymphoma as a recognized EBV-associated malignancy 1
- This represents one of the established EBV-driven malignancies
Hodgkin Lymphoma - The Strongest Evidence
The risk of EBV-positive Hodgkin lymphoma is increased 4-fold after infectious mononucleosis (relative risk 4.0) 2. This is the most robust association:
- Only EBV-positive Hodgkin lymphoma shows increased risk—there is no increased risk of EBV-negative Hodgkin lymphoma after IM 2, 3
- The median time from IM to developing EBV-positive Hodgkin lymphoma is approximately 4.1 years (range 1.8-8.3 years) 2
- In younger adults (18-44 years), the risk is even higher at 3.96-fold 3
- 55% of Hodgkin lymphomas occurring after IM contain EBV 2
General Lymphoma Risk
Recent large-scale data confirms:
- 1.75-fold increased risk of hematopoietic and lymphoid tissue tumors overall after IM 4
- A Korean national study showed 5.32-fold increased lymphoma risk in IM patients 5
Cancers NOT Associated with Infectious Mononucleosis
Based on the evidence provided, you are NOT at increased risk for:
- Acute Myeloid Leukemia (AML): No association with IM found in the evidence. The single case report 6 describes a patient with pre-existing AML who developed VZV mononucleosis syndrome—this is the reverse scenario and does not indicate IM causes AML
- Chronic Lymphocytic Leukemia (CLL): No association demonstrated
- Chronic Myeloid Leukemia (CML): No association demonstrated
- Multiple Myeloma: No association demonstrated
Additional Cancer Considerations
The evidence shows IM may also increase risk for:
- Nasopharyngeal carcinoma: 7.12-fold increased risk 5
- Prostate cancer: Possible 3.09-fold increased risk (trend level) 4
Clinical Implications
You do not require special surveillance for AML, CLL, CML, or multiple myeloma after infectious mononucleosis. The cancer risk from IM is specific to EBV-associated malignancies, particularly:
- Hodgkin lymphoma (especially in the first 5-10 years after IM)
- Burkitt lymphoma
- Other non-Hodgkin lymphomas to a lesser degree
Be vigilant for symptoms of lymphoma including:
- Persistent, painless lymph node enlargement
- Unexplained fever, night sweats, or weight loss
- The peak risk period is 2-5 years after IM diagnosis
The specificity of this association—affecting only EBV-positive lymphomas—provides strong evidence that EBV itself is causally involved in lymphoma development, rather than IM simply being a marker of immune dysfunction 2, 3.